Neogen Corporation (NEOG) Income Statement

The inflection is unmistakable in the data: gross margin held at 38-40% through 2025Q1-Q3, dipped to 41.2% in 2025Q4, then jumped to 34.4% in 2026Q1 before snapping to 47.5% in 2026Q2 and stabilizing in the 47-48% range through 2027Q1. This pattern is consistent with a one-time inventory write-down or step-up charge in early 2026 that temporarily depressed the margin before normalizing. The restored ~47% level aligns with pre-merger NEOG economics (2024Q4: 47.9%), suggesting the acquired 3M Food Safety assets are now producing at expected unit economics. However, the durability of this margin recovery depends on whether the combined entity can sustain pricing power against competitors like Hygiena and whether input cost inflation in chemical reagents remains contained.

The revenue trajectory was stubbornly negative from 2025Q1 through 2026Q4, with quarterly growth rates ranging from -5.3% to +0.7%, reflecting what appears to be integration-related disruption and possible customer defections during the 3M merger transition. The 2027Q1 print of +6.5% growth is notable not only for its magnitude but because it comes against a relatively easy comparison (2026Q1 revenue of $209.2M was one of the lowest in the series). The question for investors is whether this represents a genuine organic acceleration driven by cross-selling into the combined installed base, or simply a recovery to pre-integration revenue levels that may plateau. Sustained mid-single-digit growth would be required to justify a re-rating, but a single quarter is insufficient to confirm the trend.

The structural problem is that SG&A has not contracted commensurate with the revenue challenges. Even as gross profit compressed to $72M in 2026Q1, SG&A held at $105.9M, creating a $16M operating loss. The more recent quarters show SG&A hovering around $99-101M, which at current gross profit levels of ~$105M leaves operating income barely above zero. R&D spending is comparatively modest at $3.8-6.5M per quarter, representing only 2-3% of revenue, which raises the question of whether Neogen is underinvesting in product development relative to peers like IDEXX. The combination of a bloated SG&A base inherited from the 3M merger integration and arguably insufficient R&D creates a cost structure that appears misaligned with the company's current revenue scale, and meaningful operating leverage will require either significant overhead rationalization or substantial revenue growth that has yet to be demonstrated.